Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory ; volume:12 ; number:1 ; day:27 ; month:11 ; year:2022 ; pages:1-12 ; date:12.2022
Scientific reports ; 12, Heft 1 (27.11.2022), 1-12, 12.2022

Creator
Bai, Jie
Chiba, Asako
Murayama, Goh
Kuga, Taiga
Yahagi, Yoshiyuki
Tabe, Yoko
Tamura, Naoto
Miyake, Sachiko
Contributor
SpringerLink (Online service)

DOI
10.1038/s41598-022-24938-4
URN
urn:nbn:de:101:1-2023020821023316061004
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Bai, Jie
  • Chiba, Asako
  • Murayama, Goh
  • Kuga, Taiga
  • Yahagi, Yoshiyuki
  • Tabe, Yoko
  • Tamura, Naoto
  • Miyake, Sachiko
  • SpringerLink (Online service)

Other Objects (12)

Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response

Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study

Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?

Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand

Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis

Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis

Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?

Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients

Related objects